Form SC 13D Quotient Ltd Filed by: Bracebridge Capital, LLC

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. ___)*

 

 

QUOTIENT LIMITED

(Name of Issuer)

Ordinary Shares, nil par value

(Title of Class of Securities)

G73268149

(CUSIP Number)

John N. Spinney, Jr

Bracebridge Capital, LLC

888 Boylston Street, Suite 1500

Boston, MA 02199

(617) 497-3500

with copies to:

Sam Badawi

Ropes & Gray LLP

1211 Avenue of the Americas

New York, NY 10036-8704

(212) 596-9834

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 5, 2022

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

 

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. G73268149		Page 2 of 13

 

(1)		Names of reporting persons     FFI Fund Ltd.
(2)		Check the appropriate box if a member of a group (see instructions)     (a)  ☐        (b)  ☒
(3)		SEC use only
(4)		Source of funds (see instructions)     OO
(5)		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
(6)		Citizenship or place or organization     Cayman Islands

Number of shares  beneficially  owned by each reporting person with:				(7)		Sole voting power
				(8)		Shared voting power     94,216(1)
				(9)		Sole dispositive power
				(10)		Shared dispositive power     94,216(1)

(11)		Aggregate amount beneficially owned by each reporting person     94,216(1)
(12)		Check if the aggregate amount in Row (11) excludes certain shares (see instructions)
(13)		Percent of class represented by amount in Row (11)     2.6%(2)
(14)		Type of reporting person (see instructions)     OO

 

(1)

Includes (i) 5,133 ordinary shares, nil par value (the “Ordinary Shares”) of Quotient Limited (the “Issuer”), (ii) 56,897 Ordinary Shares issuable upon the exercise of the currently exercisable warrants with an exercise price of $30.00 per Ordinary Share (the “Warrants”) and (iii) 32,186 Ordinary Shares upon the conversion of the Issuer’s 4.75% Convertible Notes 2026 (the “Convertible Notes”).

(2)

Based on (i) 3,531,710 Ordinary Shares reported outstanding as of November 9, 2022 in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2022 (after giving effect to the 40:1 reverse stock split effected by the Issuer on November 2, 2022), plus (ii) 56,897 Ordinary Shares issuable upon the exercise of the Warrants and (iii) 32,186 Ordinary Shares issuable upon the conversion of the Convertible Notes.

CUSIP No. G73268149		Page 3 of 13

 

(1)		Names of reporting persons     FYI Ltd.
(2)		Check the appropriate box if a member of a group (see instructions)     (a)  ☐        (b)  ☒
(3)		SEC use only
(4)		Source of funds (see instructions)     OO
(5)		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
(6)		Citizenship or place or organization     Cayman Islands

Number of shares  beneficially  owned by each reporting person with:				(7)		Sole voting power
				(8)		Shared voting power     16,780(1)
				(9)		Sole dispositive power
				(10)		Shared dispositive power     16,780(1)

(11)		Aggregate amount beneficially owned by each reporting person     16,780(1)
(12)		Check if the aggregate amount in Row (11) excludes certain shares (see instructions)
(13)		Percent of class represented by amount in Row (11)     0.5%(2)
(14)		Type of reporting person (see instructions)     OO

 

(1)	Includes (i) 877 Ordinary Shares, (ii) 9,731 Ordinary Shares issuable upon the exercise of the Warrants and (iii) 6,172 Ordinary Shares upon the conversion of the Convertible Notes.

(2)

Based on (i) 3,531,710 Ordinary Shares reported outstanding as of November 9, 2022 in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2022 (after giving effect to the 40:1 reverse stock split effected by the Issuer on November 2, 2022), plus (ii) 9,731 Ordinary Shares issuable upon the exercise of the Warrants and (iii) 6,172 Ordinary Shares issuable upon the conversion of the Convertible Notes.

CUSIP No. G73268149		Page 4 of 13

 

(1)		Names of reporting persons     Olifant Fund, Ltd.
(2)		Check the appropriate box if a member of a group (see instructions)     (a)  ☐        (b)  ☒
(3)		SEC use only
(4)		Source of funds (see instructions)     OO
(5)		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
(6)		Citizenship or place or organization     Cayman Islands

Number of shares  beneficially  owned by each reporting person with:				(7)		Sole voting power
				(8)		Shared voting power     14,707(1)
				(9)		Sole dispositive power
				(10)		Shared dispositive power     14,707(1)

(11)		Aggregate amount beneficially owned by each reporting person     14,707(1)
(12)		Check if the aggregate amount in Row (11) excludes certain shares (see instructions)
(13)		Percent of class represented by amount in Row (11)     0.4%(2)
(14)		Type of reporting person (see instructions)     OO

 

(1)	Includes (i) 742 Ordinary Shares, (ii) 8,234 Ordinary Shares issuable upon the exercise of the Warrants and (iii) 5,731 Ordinary Shares upon the conversion of the Convertible Notes.

(2)

Based on (i) 3,531,710 Ordinary Shares reported outstanding as of November 9, 2022 in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2022 (after giving effect to the 40:1 reverse stock split effected by the Issuer on November 2, 2022), plus (ii) 8,234 Ordinary Shares issuable upon the exercise of the Warrants and (iii) 5,731 Ordinary Shares issuable upon the conversion of the Convertible Notes.

CUSIP No. G73268149		Page 5 of 13

 

(1)		Names of reporting persons     Bracebridge Capital, LLC
(2)		Check the appropriate box if a member of a group (see instructions)     (a)  ☐        (b)  ☒
(3)		SEC use only
(4)		Source of funds (see instructions)     OO
(5)		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
(6)		Citizenship or place or organization     Delaware

Number of shares  beneficially  owned by each reporting person with:				(7)		Sole voting power
				(8)		Shared voting power     125,703(1)
				(9)		Sole dispositive power
				(10)		Shared dispositive power     125,703(1)

(11)		Aggregate amount beneficially owned by each reporting person     125,703(1)
(12)		Check if the aggregate amount in Row (11) excludes certain shares (see instructions)
(13)		Percent of class represented by amount in Row (11)     3.4%(2)
(14)		Type of reporting person (see instructions)     IA

 

(1)	Includes (i) 6,752 Ordinary Shares, (ii) 74,862 Ordinary Shares issuable upon the exercise of the Warrants and (iii) 44,089 Ordinary Shares issuable upon the conversion of the Convertible Notes.

(2)

Based on (i) 3,531,710 Ordinary Shares reported outstanding as of November 9, 2022 in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2022 (after giving effect to the 40:1 reverse stock split effected by the Issuer on November 2, 2022), plus (ii) 74,862 Ordinary Shares issuable upon the exercise of the Warrants and (iii) 44,089 Ordinary Shares issuable upon the conversion of the Convertible Notes.

CUSIP No. G73268149		Page 6 of 13

 

 

Item 1.

SECURITY AND ISSUER.

This Schedule 13D (this “Schedule 13D”) relates to the ordinary shares, nil par value (the “Ordinary Shares”) of Quotient Limited, incorporated in Jersey, Channel Islands (the “Issuer”). The address of the principal executive offices of the Issuer is Business Park Terre Bonne, Route de Crassier 13, 1262 Eysins, Switzerland.

 

Item 2.

IDENTITY AND BACKGROUND.

This statement is filed by Bracebridge Capital, LLC, a Delaware limited liability company (“Bracebridge”), FFI Fund Ltd., a Cayman Islands entity (“FFI”), FYI Ltd., a Cayman Islands entity (“FYI”) and Olifant Fund, Ltd, a Cayman Islands entity (“Olifant” and, together with FFI and FYI (the “Bracebridge Funds” and, together with Bracebridge, FFI, and FYI the “Reporting Persons”). Bracebridge is the investment adviser to the Bracebridge Funds and is primarily in the business of providing investment advice to private funds. The Bracebridge Funds are private funds that are primarily engaged in making investments. The agreement among the Reporting Persons relating to the joint filing of this Schedule 13D is attached as Exhibit 99.1 hereto.

The principal business address of the Reporting Persons is 888 Boylston Street, Suite 1500, Boston, MA, 02199.

The information required by General Instruction C to Schedule 13D is attached hereto as Schedule A and is hereby incorporated by reference.

During the last five years, none of the Reporting Persons nor, to the knowledge of the Reporting Persons, without independent verification, any of the persons listed in Schedule A (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Item 3.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

The source of funding for the purchase of the Ordinary Shares and the Issuer’s 4.75% Convertible Notes 2026 (the “Convertible Notes”) was capital contributed by the investors in the Bracebridge Funds.

The Reporting Persons received currently exercisable warrants with an exercise price of $30.00 per Ordinary Share (the “Warrants”) as consent consideration paid to them as holders of the Company’s 12% Senior Secured Notes due 2025 (the “Senior Secured Notes”) in connection with the Sixth Supplemental Indenture, dated as of July 6, 2022, between the Issuer, the guarantors party thereto and U.S. Bank National Association, as trustee and collateral agent, to the indenture governing the Senior Secured Notes.

 

Item 4.

PURPOSE OF TRANSACTION.

The Reporting Persons originally acquired the securities reported herein for investment purposes in the ordinary course of business, and not with the purpose or effect of changing or influencing control or management of the Issuer.

CUSIP No. G73268149		Page 7 of 13

 

The Bracebridge Funds entered into an agreement (together with all exhibits, annexes and schedules thereto, the “Transaction Support Agreement”, attached as Exhibit 99.2 hereto), dated as of December 5, 2022, with (i) the Issuer, (ii) other holders of the Issuer’s outstanding Senior Secured Notes issued under that certain Indenture, dated as of October 14, 2016 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the “Senior Secured Notes Indenture”), by and among the Issuer, the guarantors party thereto, and U.S. Bank Trust Company, National Association, as trustee, representing all holders of the Senior Secured Notes and (iii) other holders of the Issuer’s convertible notes (the “Convertible Notes”) issued under that certain Indenture, dated as of May 26, 2021 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the “Convertible Notes Indenture” and together with the Senior Secured Notes Indenture, the “Indentures”), by and among the Issuer, the guarantors party thereto, and Wilmington Savings Fund Society, FSB, as trustee representing more than 99% of all holders of the Convertible Notes (such holders of the Senior Secured Notes and Convertible Notes, including, the Bracebridge Funds, collectively, the “Consenting Noteholders”), whereby the Consenting Noteholders have agreed to support a restructuring of the Issuer’s balance sheet, which is intended to be effectuated pursuant to a set of transactions to be commenced by the Issuer (collectively, the “Transactions”).

In connection with the Transactions, all of the Issuer’s outstanding equity securities (including its Ordinary Shares, preferred shares, options and warrants) are expected to be extinguished and cancelled for no consideration (or nominal consideration if required as a matter of Jersey law). Accordingly, the Issuer intends to delist its Ordinary Shares from the NASDAQ Global Market as soon as practicable. The Transactions are intended to reduce the Issuer’s debt obligations and inject liquidity into the Issuer’s business as necessary to effectuate its strategy shift.

Under the Transaction Support Agreement, the Issuer and the Consenting Noteholders have agreed to act in good faith to consummate the Transactions and have undertaken other customary commitments to one another. The Consenting Noteholders have also agreed to forbear from exercising, for so long as the Transaction Support Agreement is in full force and effect, any and all rights and remedies in contravention of the Transaction Support Agreement, which are or become available to them in respect of the Senior Secured Notes, the Convertible Notes or any other claims or interests in connection therewith.

The Transaction Support Agreement contains certain deadlines relating to the Transactions, including deadlines (collectively, the “Milestones”) for implementing the Transactions either through (i) the filing of a petition for relief under chapter 11 of the U.S. Bankruptcy Code in order to effect a plan of reorganization (the “Plan”) that implements a fully consensual restructuring or such other method of implementation of the Transactions as the Requisite Consenting Holders (as defined below) direct, subject to the Fiduciary Out (as defined below) (the “Consensual Transaction”) or (ii) parallel creditor schemes of arrangements in England and Jersey (the “Fallback Scheme”), in each case as described in, and contemplated under, the Implementation Steps Memorandum attached to the Transaction Support Agreement as Exhibit B (the “Implementation Steps Memo”), as well as an outside date of May 1, 2023 for the consummation of a Consensual Transaction or Fallback Scheme (such date, the “Outside Date”).

If the board of directors of the Issuer (the “Board”) reasonably determines, after considering the advice of outside counsel, that taking certain actions, or refraining to take certain actions, is reasonably required for the Board to comply with its fiduciary duties (including if such actions would require expenditures in excess of the Issuer’s available liquidity), the Transaction Support Agreement provides that the Board may elect not to take, or refrain to take, such actions (such election, the “Fiduciary Out”). The Issuer may terminate the Transaction Support Agreement upon, among other circumstances, uncured material breaches of the Transaction Support Agreement by a Consenting Noteholder or a determination by the Board that termination is required pursuant to the Fiduciary Out.

CUSIP No. G73268149		Page 8 of 13

 

The Consenting Noteholders have termination rights that may, as a general matter, be exercised by (i) holders of the Senior Secured Notes holding at least a majority of the outstanding Senior Secured Notes and (ii) holders of the Convertible Notes holding at least a majority of the outstanding Convertible Notes, and, in the case of both subsection (i) and (ii), each of the Specified Noteholders (each as defined in the Transaction Support Agreement) (the holders in (i) and (ii) together, “Requisite Consenting Noteholders”), which termination rights include, among other circumstances, exercise of the Fiduciary Out by the Issuer, material breaches of the Transaction Support Agreement by the Issuer and the failure of the Issuer to meet any Milestone.

Under the terms of the Transaction Support Agreement:

 

•

The holders of the Senior Secured Notes have agreed to fund their commitment portion of $10 million of indebtedness (the “Bridge Notes”) to the Issuer by no later than December 13, 2022.

 

•

Each noteholder under the Senior Secured Notes Indenture has agreed to exchange (i) such notes held by it (other than the Bridge Notes) for newly issued senior secured debt at a discount, and (ii) its Bridge Notes for newly issued senior secured debt at face value.

 

•

Certain holders of Senior Secured Notes, including the Bracebridge Funds, have also agreed to purchase an aggregate of $13 million in new common equity at a 35% discount to a total equity value of $50 million (the “Agreed Equity Value”). In addition, each such Senior Secured Noteholder will receive its applicable share of an aggregate of $20 million in new common equity at the Agreed Equity Value.

 

•

The Consenting Holders who own Convertible Notes, including the Bracebridge Funds, have agreed that their Convertible Notes shall be extinguished for no value, other than for the purchase right set forth immediately below.

 

•

Such holders of Convertible Notes have agreed to purchase an aggregate of $28 million in new common equity at a 35% discount to the Agreed Equity Value. In addition, each such Convertible Noteholder will receive its applicable share of an aggregate of $30 million in new common equity at the Agreed Equity Value.

 

•

The newly issued senior secured debt is expected to (i) be secured by a first lien on substantially the same collateral and assets as were subject to liens under the Senior Secured Notes Indenture, (ii) mature 5 years (or, with the consent of holders of the Senior Secured Notes holding at least a majority of the outstanding Senior Secured Notes and each of the Specified Noteholders, 7 years) from the closing date, and (iii) bear interest at a rate of 12% payable in kind for the first three years (or, with certain consent, two years) following the closing date, and thereafter payable in cash. The new senior secured debt is also expected to provide for a mandatory repurchase with 100% of the net proceeds from certain sales, include covenants and events of default substantially similar to those existing under the Senior Secured Notes Indenture, and be redeemable at a price of 103% of the principal amount thereof, plus accrued and unpaid interest, for the first 2 years after issuance, and at par (plus accrued and unpaid interest) thereafter.

 

•

All existing equity of the Issuer will be extinguished and cancelled for no consideration (or nominal consideration if required as a matter of Jersey law).

Each of the Transactions is on terms and conditions as set forth in the Transaction Support Agreement and the exhibits thereto. The Transaction Support Agreement contains certain representations, warranties and other agreements by the Issuer and the Consenting Noteholders. The parties’ obligations thereunder are subject to various terms and conditions and termination provisions as set forth therein.

CUSIP No. G73268149		Page 9 of 13

 

The foregoing description of the Transaction Support Agreement and the Transactions is a summary only, does not purport to be complete and is qualified in its entirety by reference to the full text of the Transaction Support Agreement (including the exhibits thereto), a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The Reporting Persons and its representatives may from time to time continue to engage in discussions with members of management, the Board, the consenting Noteholders, other current or prospective shareholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit and other third parties regarding a variety of matters relating to the Issuer, which may include, among other things, the Issuer’s business, management, capital structure and allocation, corporate governance, Board composition and strategic alternatives and direction, and may take other steps seeking to bring about changes to increase shareholder value as well as pursue other plans or proposals that relate to or could result in any of the matters set forth in clauses (a)-(j) of Item 4 of Schedule 13D.

The Reporting Persons intend to review its investment in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the outcome of any discussions referenced above, the Issuer’s financial position, results and strategic direction, actions taken by the Issuer’s management and the Board, price levels of the Ordinary Shares, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to its investment in the Issuer as it deems appropriate, including, without limitation, exchanging information with the Issuer or other third parties pursuant to appropriate confidentiality or similar agreements; proposing changes in the Issuer’s operations, management, Board, governance or capitalization; acquiring additional Ordinary Shares and/or other equity, debt, notes, instruments or other securities of the Issuer (collectively, “Securities”) or disposing of some or all of the Securities beneficially owned by it, in public market or privately negotiated transactions; entering into financial instruments or other agreements that increase or decrease the Reporting Persons’ economic exposure with respect to its investment in the Issuer and/or otherwise changing its intention with respect to any and all matters referred to in Item 4 of Schedule 13D.

 

Item 5.

INTEREST IN SECURITIES OF THE ISSUER.

The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Statement is incorporated by reference in its entirety into this Item 5.

(a), (b) The percentage of Ordinary Shares beneficially owned by the Reporting Persons is based on 3,531,710 Ordinary Shares reported outstanding as of November 9, 2022 in the Issuer’s Form 10-Q for the quarterly period ended September 30, 2022 (after giving effect to the 40:1 reverse stock split effected by the Issuer on November 2, 2022), plus (ii) the Ordinary Shares issuable upon the exercise of Warrants and the conversion of the Convertible Notes beneficially owned by such Reporting Persons.    Each of the Reporting Persons has the power to vote and dispose of the Ordinary Shares beneficially owned by such entity (as described above), and each of the Reporting Persons expressly disclaims beneficial ownership of any Ordinary Shares not owned directly by it except to the extent of any pecuniary interest therein. Bracebridge, as the investment manager of each of the Bracebridge Funds, has the authority to vote and dispose of all of the Ordinary Shares reported in this Schedule 13D, but expressly disclaims beneficial ownership of any Ordinary Shares not owned directly by it except to the extent of its pecuniary interest therein.

CUSIP No. G73268149		Page 10 of 13

 

The Transaction Support Agreement may result in the Reporting Persons being deemed a “group” with the other Consenting Noteholders. The other Consenting Noteholders may separately report their beneficial ownership of the Ordinary Shares on Schedule 13D with the SEC and reference is hereby made to any such filings for the beneficial ownership of Ordinary Shares of such other Consenting Noteholders and any changes thereto. The Reporting Persons expressly disclaim beneficial ownership of any securities beneficially owned by the other Consenting Noteholders.

Pursuant to the terms of the Warrants and Convertible Notes, no Reporting Person can exercise any of the Warrants or convert any of the Convertible Notes if such Reporting Person, together with any other Person, including, without limitation, the other Consenting Noteholders, with whom such Reporting Person may be deemed to be a “group” within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended would beneficially own, after such exercise, more than 9.90% of the outstanding Ordinary Shares.

(c) The Reporting Persons have not effected transactions in the Ordinary Shares during the past sixty days.

(d) No person other than the Reporting Persons are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Ordinary Shares held by the Reporting Persons.

(e) Not applicable.

 

Item 6.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

The information set forth in Items 4 and 5 is incorporated herein by reference.

Other than as described in this Item 6 and Items 4 and 5, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any other securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.

 

Item 7.

MATERIALS TO BE FILED AS EXHIBITS.

 

Exhibit 99.1:		Joint Filing Agreement
Exhibit 99.2:		Transaction Support Agreement (incorporated by reference to Exhibit 10.1 attached to the Issuer’s Current Report on Form 8-K filed with the SEC on December 8, 2022).

CUSIP No. G73268149		Page 11 of 13

 

Signatures

After reasonable inquiry and to the best knowledge and belief of the undersigned, such person certifies that the information set forth in this Statement with respect to such person is true, complete and correct.

Date: December 15, 2022

 

CUSIP No. G73268149		Page 12 of 13

 

Schedule A

The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director and/or executive officer of Bracebridge Capital, LLC:

 

Name		Position and Present Principal Occupation		Citizenship		Business Address
John N. Spinney		Chief Financial Officer and Chief Operating Officer		United States		c/o Bracebridge Capital, LLC, 888 Boylston Street, Suite 1500, Boston, MA, 02199
William D. Townley		General Counsel		United States		c/o Bracebridge Capital, LLC, 888 Boylston Street, Suite 1500, Boston, MA, 02199
Silvestre A. Fontes		Chief Compliance Officer		United States		c/o Bracebridge Capital, LLC, 888 Boylston Street, Suite 1500, Boston, MA, 02199
Nancy G. Zimmerman		Managing Member		United States		c/o Bracebridge Capital, LLC, 888 Boylston Street, Suite 1500, Boston, MA, 02199
Gabriel B. Sunshine		Managing Member		United States		c/o Bracebridge Capital, LLC, 888 Boylston Street, Suite 1500, Boston, MA, 02199

The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director and/or executive officer of FFI Fund Ltd:

 

Name		Position and Present Principal Occupation		Citizenship		Business Address
Lori Webb-Griffith		Director		British Overseas Territories—Cayman Islands		c/o FFI Fund Ltd, One Nexus Way, Suite 5B201, Camana Bay, Grand Cayman KY1-1108, Cayman Islands
Alaina Danley		Director		United States		c/o FFI Fund Ltd, One Nexus Way, Suite 5B201, Camana Bay, Grand Cayman KY1-1108, Cayman Islands

CUSIP No. G73268149		Page 13 of 13

 

The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director of FYI Ltd:

 

Name		Position and Present Principal Occupation		Citizenship		Business Address
Lori Webb-Griffith		Director		British Overseas Territories—Cayman Islands		c/o FYI Ltd, One Nexus Way, Suite 5B201, Camana Bay, Grand Cayman KY1-1108, Cayman Islands
Alaina Danley		Director		United States		c/o FYI Ltd, One Nexus Way, Suite 5B201, Camana Bay, Grand Cayman KY1-1108, Cayman Islands

The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director of and/or executive officer Olifant Fund, Ltd:

 

Name		Position and Present Principal Occupation		Citizenship		Business Address
Lori Webb-Griffith		Director		British Overseas Territories—Cayman Islands		c/o Olifant Fund, Ltd, One Nexus Way, Suite 5B201, Camana Bay, Grand Cayman KY1-1108, Cayman Islands
Alaina Danley		Director		United States		c/o Olifant Fund, Ltd, One Nexus Way, Suite 5B201, Camana Bay, Grand Cayman KY1-1108, Cayman Islands